EGFR and neoplasm: This was evident in a clinical trial where the combination of everolimus and the epidermal growth factor receptor (EGFR) inhibitor gefitinib showed limited effectiveness in reducing tumour activity in patients diagnosed with metastatic castration-resistant prostate cancer [143].